Medically reviewed by Drugs.com. Last updated on Nov 15, 2018.
Applies to the following strengths: 4 mg/mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Mycosis Fungoides
1 mg/kg IV over at least 60 minutes on days 1, 8, 15, and 22 of the first 28-day cycle, then on days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity
-Premedicate patients with diphenhydramine and acetaminophen for the first infusion.
-Administer within 2 days of the scheduled dose. If a dose is missed, administer the next dose as soon as possible and resume dosing schedule.
-Do not administer subcutaneously or by rapid IV administration.
Uses: For relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Dose Modifications for Dermatologic Toxicity:
-If mild (Grade 1) rash occurs, consider topical corticosteroids.
-If moderate or severe (Grade 2 or 3) rash occurs, interrupt therapy and administer at least 2 weeks of topical corticosteroids. If rash improves to Grade 1 or less, therapy may be resumed.
-Permanently discontinue therapy for life-threatening (Grade 4) rash or for Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). If SJS or TEN is suspected, discontinue therapy and do not resume unless SJS or TEN has been excluded and the cutaneous reaction has resolved to Grade 1 or less.
Dose Modifications for Infusion Reactions:
-If an infusion reaction occurs, administer premedication (i.e., diphenhydramine and acetaminophen) for subsequent infusions.
-Temporarily interrupt the infusion for mild to severe (Grades 1 to 3) infusion
reactions and treat symptoms. Reduce the infusion rate by at least 50% when restarting the infusion after symptoms resolve. If reaction recurs and is unmanageable, discontinue infusion.
-Permanently discontinue therapy for a life-threatening (Grade 4) infusion reaction.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Administer infusion solution over at least 60 minutes through an IV line containing a sterile, low protein binding, 0.22 micron (or equivalent) in-line filter.
-Do not mix this drug with other drugs.
-Do not coadminister other drugs through the same IV line.
-Store unused vials under refrigeration at 2C to 8C (36F to 46F) in original package to protect from light until time of use.
-Do not freeze.
-Do not shake.
-After preparation, infuse the solution immediately, or store under refrigeration at 2C to 8C (36F to 46F) for no more than 4 hours from the time of infusion preparation.
-Visually inspect drug product solution for particulate matter and discoloration prior to administration. The solution should be clear to slightly colorless opalescent. Discard the vial if cloudiness, discoloration, or particulates are observed.
-Calculate the dose (mg/kg) and number of vials needed to prepare the solution based on patient weight.
-Aseptically withdraw the required dose into the syringe and transfer into an IV bag containing 0.9% sodium chloride injection. The final concentration of the diluted solution should be between 0.1 mg/mL to 3 mg/mL.
-Mix diluted solution by gentle inversion. Do not shake.
-Discard any unused portion left in the vial.
-The diluted solution is compatible with polyvinyl chloride (PVC) or polyolefin (PO) infusion bags.
-Compatible with 0.9% sodium chloride injection.
-Read the patient information leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about mogamulizumab
- Side Effects
- During Pregnancy or Breastfeeding
- Drug Interactions
- En Español
- Drug class: miscellaneous antineoplastics
Other brands: Poteligeo